424 related articles for article (PubMed ID: 17592270)
21. Neuroendocrine differentiation in thymic epithelial tumors with special reference to thymic carcinoma and atypical thymoma.
Hishima T; Fukayama M; Hayashi Y; Fujii T; Arai K; Shiozawa Y; Funata N; Koike M
Hum Pathol; 1998 Apr; 29(4):330-8. PubMed ID: 9563781
[TBL] [Abstract][Full Text] [Related]
22. Expression of cathepsins V and S in thymic epithelial tumors.
Kiuchi S; Tomaru U; Ishizu A; Imagawa M; Kiuchi T; Iwasaki S; Suzuki A; Otsuka N; Deguchi T; Shimizu T; Marukawa K; Matsuno Y; Kasahara M
Hum Pathol; 2017 Feb; 60():66-74. PubMed ID: 27771373
[TBL] [Abstract][Full Text] [Related]
23. Immunohistological analysis of thymoma by molecules differentially expressed in the thymic cortex and medulla, and its application in the differential diagnosis of thymoma from esophageal and lung cancer.
Shiraishi J; Utsuyama M; Akashi T; Nemoto T; Ohashi K; Akamatsu H; Sunamori M; Kitagawa M; Hirokawa K
Pathol Res Pract; 2001; 197(9):611-9. PubMed ID: 11569925
[TBL] [Abstract][Full Text] [Related]
24. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms.
Datta MW; Shahsafaei A; Nadler LM; Freeman GJ; Dorfman DM
Appl Immunohistochem Mol Morphol; 2000 Sep; 8(3):210-5. PubMed ID: 10981873
[TBL] [Abstract][Full Text] [Related]
25. Intrathyroid epithelial thymoma (ITET) and carcinoma showing thymus-like differentiation (CASTLE): CD5-positive neoplasms mimicking squamous cell carcinoma of the thyroid.
Kakudo K; Bai Y; Ozaki T; Homma K; Ito Y; Miyauchi A
Histol Histopathol; 2013 May; 28(5):543-56. PubMed ID: 23233417
[TBL] [Abstract][Full Text] [Related]
26. [Correlation between MMP-2 activation and MT1-MMP mRNA expression in thymic epithelial tumors].
Wang Y; Ueda Y; Shimasaki M; Liu N; Wang EH
Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):18-23. PubMed ID: 16608644
[TBL] [Abstract][Full Text] [Related]
27. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes.
Thomas de Montpréville V; Quilhot P; Chalabreysse L; De Muret A; Hofman V; Lantuéjoul S; Parrens M; Payan MJ; Rouquette I; Secq V; Girard N; Besse B; Marx A; Molina TJ
Pathol Res Pract; 2015 Dec; 211(12):996-1002. PubMed ID: 26534878
[TBL] [Abstract][Full Text] [Related]
28. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
Chan JK; Tsang WY; Seneviratne S; Pau MY
Am J Surg Pathol; 1995 Oct; 19(10):1115-23. PubMed ID: 7573670
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma.
Du MJ; Shen Q; Yin H; Rao Q; Zhou MX
Pathol Res Pract; 2016 Nov; 212(11):1048-1051. PubMed ID: 27688088
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K
Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277
[TBL] [Abstract][Full Text] [Related]
31. Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma.
Tateyama H; Eimoto T; Tada T; Hattori H; Murase T; Takino H
Am J Clin Pathol; 1999 Feb; 111(2):235-40. PubMed ID: 9930146
[TBL] [Abstract][Full Text] [Related]
32. Difference in distribution profiles between CD163+ tumor-associated macrophages and S100+ dendritic cells in thymic epithelial tumors.
Omatsu M; Kunimura T; Mikogami T; Shiokawa A; Nagai T; Masunaga A; Kitami A; Suzuki T; Kadokura M
Diagn Pathol; 2014 Dec; 9():215. PubMed ID: 25499804
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups.
Sung YM; Lee KS; Kim BT; Choi JY; Shim YM; Yi CA
J Nucl Med; 2006 Oct; 47(10):1628-34. PubMed ID: 17015898
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of S100A9 for diagnosis of intrathyroid epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE).
Ito Y; Miyauchi A; Arai K; Nozawa R; Miya A; Kobayashi K; Nakamura Y; Kakudo K
Pathology; 2006 Dec; 38(6):541-4. PubMed ID: 17393982
[TBL] [Abstract][Full Text] [Related]
35. Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma.
Pfister F; Hussain H; Belharazem D; Busch S; Simon-Keller K; Becker D; Pfister E; Rieker R; Ströbel P; Marx A
Histopathology; 2017 Apr; 70(5):693-703. PubMed ID: 27791295
[TBL] [Abstract][Full Text] [Related]
36. Thymic epithelial neoplasms with sebaceous differentiation: a clinicopathological and immunohistochemical study of 8 cases.
Kalhor N; Moran CA
Hum Pathol; 2019 Apr; 86():124-128. PubMed ID: 30537491
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
Kojika M; Ishii G; Yoshida J; Nishimura M; Hishida T; Ota SJ; Murata Y; Nagai K; Ochiai A
Mod Pathol; 2009 Oct; 22(10):1341-50. PubMed ID: 19648882
[TBL] [Abstract][Full Text] [Related]
38. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Marchevsky AM; Walts AE
Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic study of thymic epithelial tumors].
Adachi K; Hosaka N; Takao M; Fujinaga K
Kyobu Geka; 2005 Feb; 58(2):119-22. PubMed ID: 15724473
[TBL] [Abstract][Full Text] [Related]
40. An immunohistochemical study of thymic epithelial tumors. I. Epithelial component.
Kodama T; Watanabe S; Sato Y; Shimosato Y; Miyazawa N
Am J Surg Pathol; 1986 Jan; 10(1):26-33. PubMed ID: 2420219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
